A COMPREHENSIVE STUDY ON EBOLA (EBOV) VIRUS: A THREAT TO HUMAN EXISTENCE

Taneja Mani1*, Malik Anu2, Singh Manisha1, Das Doli1

1Assistant Professor, Gurugram Global College of Pharmacy, Farrukhnagar, Gurugram, Haryana, India-122506
2Assistant Professor, RP Institute of Information and Technology, Bastara, Karnal, Haryana, India

ABSTRACT

Ebola hemorrhagic disease is a severe, an acute, often fatal disease in humans and non-humans which is caused by infection with a virus of family: Filoviridae, genus: Ebola virus. The incubation period of ebola virus disease (EVD) varies from 2-21 days, with an observed average of 8 to 10 days by following introduction of Ebola virus in the human population through animal-to-human transmission, person-to-person transmission by direct contact body fluids/secretions of infected persons. The most common symptoms include sudden onset of fever, intense weakness, muscle pain, headache and sore throat, vomiting, diarrhea, rash, impaired kidney and liver function, and at advanced stage both internal and external bleeding. The virus is transmitted by contact with body fluids of infected humans or an animal is primarily responsible for the virus outbreak. Fruit bats are considered as the natural reservoirs of the virus. The most general assays used for antibody detection are direct IgG and IgM ELISAs and IgM capture ELISA. An IgM or rising IgG titer (four-fold) contributes to strong presumptive diagnosis. Currently neither a licensed vaccine nor an approved treatment is available for human use. In this review, the Ebola virus: life cycle and pathogenicity in humans, diagnosis, pharmacotherapy and their prevention is summarized.

Keywords: Filoviridae, Ebola, Outbreak, Transmission, Symptoms, Hemorrhagic fever.

1. INTRODUCTION

Ebola, previously known as Ebola hemorrhagic disease, is a severe, an acute, often fatal disease in humans and non-humans. It is a rare and deadly disease caused by infection with a virus of family: Filoviridae, genus: Ebola virus. There are five identified ebola virus species, four of which have caused disease in humans known as Ebola Virus Diseases (EVD)1,2. Ebola virus has caused the majority of human deaths from EVD, and is the cause of the 2013-2014 ebola virus epidemics in West Africa, which has resulted in at least 20,834 suspected causes and 8,251 confirmed deaths1. There are no licensed specific treatments or vaccine available for use in peoples and animals.

There are five identified ebola virus species which differ in their virulence for humans i.e. Zaire ebola virus; Sudan ebola virus; Tai Forest ebola virus (Cote d’Ivoire Ebola virus); Bundibugyo ebola virus caused disease in humans and the fifth Reston ebola virus has caused disease in nonhuman primates (such as Monkeys, gorillas and chimpanzees) but not in humans1,2.

The incubation period of ebola virus disease (EVD) varies from 2-21 days, with an observed average of 8 to 10 days. Following the introduction of Ebola virus in the human population through animal-to-human transmission, person-to-person transmission by direct contact body fluids/secretions of infected persons is considered the principal mode of transmission. Indirect contact with environment and families soiled with contaminated body fluids (e.g needles) may also occur.
Airborne transmission has not been documented during previous EVD outbreaks. There is no risk of transmission during the incubation period.

The most common symptoms experienced by persons infected with the virus are the sudden onset of fever, intense weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhea, rash, impaired kidney and liver function, and at advanced stage both internal and external bleeding. Laboratory findings include low white blood cells and platelet counts and elevated liver enzymes.

2. EPIDEMIOLOGY

The filo viruses were first recognized in 1967, when the inadvertent importation of infected monkeys from Uganda into Germany and Yugoslavia resulted in an explosive outbreak of severe illness among vaccine plant workers who came into direct contact with animals by killing them, removing their kidneys, or preparing primary cell cultures for polio vaccine production.

EVD first appeared in 1976 in two simultaneous outbreaks, one in Nzara, Sudan and other in Yambuku, Democratic republic of Congo. The latter occurred in a village near the Ebola River, from which the disease takes its name.

Ebola virus was first discovered in 1976. There have been more cases and deaths in the outbreak than all others combined. It has also spread between countries starting in guinea then spreading across land borders to Sierra Leone and Liberia, by air(one traveller only) to Nigeria, and by land (one traveler ) to Senegal.

2014 outbreak in West Africa: By far, the largest outbreak of Ebola virus disease ever recorded is currently occurring in West Africa with the Zaire species of the virus. Although most previous Ebola outbreaks occurred in central Africa, this outbreak started in the West Africans nation of Guinea in late 2013 and was confirmed by the World health organization (WHO) in March 2014. The initial case was a 2 year old child in Guinea, who developed fever, vomiting, and black stools, without other evidence of hemorrhage. The outbreak subsequently spread to Liberia, Sierra Leone, Nigeria, Senegal and Mali. Sequence analysis of viruses isolated from patients in Sierra Leone indicates that the epidemic has resulted from sustained person-to-person transmission, without additional introductions from animal reservoirs. The case-fatality rate has been estimated to be approximately 70 percent.

As of October 19, 2014, the cumulative number of portable, suspected, and laboratory –confirmed cases attributed to Ebola virus is 9936, including 4877 deaths. These include 443 health care workers, of whom approximately 55 percent have died. However, Nigeria and Senegal have not reported any new cases since September 5, 2014, and respectively.

Cases of Ebola virus disease related to this outbreak have also been reported outside of West Africa. On September 30, 2014, the first travel-associated case of Ebola was reported in the United States. An individual who traveled from Liberia to Dallas, Texas first developed clinical findings consistent with ebola virus disease approximately five days after arriving in the United States. The patient was asymptomatic prior to and during the flight. Two health care workers involved in the care subsequently developed ebola virus disease. So, it was concluded to say that person to person transmission was for this disorder.

2014 outbreak in the democratic republic of Congo: In august of 2014, an outbreak of Ebola virus disease was reported in the democratic republic of Congo. The index case was a pregnant woman who prepared bush meat from an animal that had been killed by her husband. As of October 20, 2014, a total of 66 cases of EVD (confirmed and probable), including 49 deaths, have been connected to this outbreak.

Outbreak in India: India which had so far remained unscathed from the virus, has diagnosed a fresh case of it after an Indian, semen sample showed traces of ebola virus. The man, a 26 year old Indian, working in Liberia, was earlier treated and cured of the deadly virus, is kept in isolation at delhi’s airport health organization quarantine centre.

2.1. Virus Reservoir

The natural reservoir host of Ebola has not yet been identified; the manner by which the virus first appears in a human at the start of an outbreak is unknown. Perhaps the greatest mysteries regarding the filoviruses are the identity of their natural reservoir and the mode of transmission from the reservoir to wild apes and humans. When an infection does not occur in humans, there are several ways the virus can be spread to others.

3. TRANSMISSION

Experiments in laboratory animals indicate that filoviruses can initiate infection via many routes, including ingestion, inhalation, or passage through breaks in the skin. Non human’s primates can be infected with Ebola or Marburg virus through droplet inoculation of virus into the mouth or eyes, suggesting that cases of human infection result from the inadvertent of virus to these sites from the patient’s own contaminated hands.

3.1. Person to person: Person to person transmission occurs through direct contact of broken skin or unprotected mucous membranes with virus-containing body fluids like blood feces and vomit from which the developed signs and symptoms of illness. The viruses that cause Ebola are often spread among families and friends, because they come in close contact with blood or body fluids when caring for ill person. It has been also detected in urine, semen and breast milk. Saliva and tears also harbor the virus. Thus, contact with any of these fluids can pose potential risk. During the outbreak of Ebola, the disease can spread quickly with in healthcare settings, such as clinics or hospitals.

3.2. Direct contact with the objects (like needles and syringes) that have been contaminated with the blood or
body fluids of an infected person or with infected animals.

Ebola virus may also be transmitted through contact with previously contaminated surfaces and objects. Limited data suggest that viable virus may exist for up to several days on fomites. Although there are no high-quality data to confirm transmission through this type of exposure, the potential risk can be reduced by proper environmental learning.

4. INCUBATION PERIODS

Patients with EVD typically have an abrupt onset of symptoms 8-12 days after exposure (range 2 to 21 days). However, all asymptomatic individuals should be assumed to have high levels of virus in the blood and other body fluids and appropriate safety precautions should be taken.

5. SYMPTOMS AND SIGNS

The most common sign and symptoms reported from west Africa during the 2014 outbreak include: fever (85 percent), fatigue (76 percent), vomiting (68 percent), diarrhea (66 percent) and loss of appetite (65 percent). Important clinical findings of patients with Ebola and Marburg virus disease are as follows:

- **Nonspecific flu-like symptoms**: Ebola and Marburg hemorrhagic fever typically begin with the abrupt onset of fever, chills and general malaise. Other signs and symptoms include weakness, anorexia, severe headache, and pain in the muscles of the trunk and lower back. Multisystem involvement follows that includes prostration; nausea, vomiting, abdominal pain, diarrhea and pancreatitis; chest pain, cough, and pharyngitis; vascular and neurological manifestations.

- **Rash**: Some patients develop a diffuse erythematous, nonpruritic maculopapular rash by day five to seven of illness. The rash usually involves the face, neck, trunk, and arms, and can desquamate in survivors.

- **Gastrointestinal**: Gastrointestinal signs and symptoms usually develop several days after the initial presentation. These include watery diarrhea, nausea, vomiting, and abdominal pain.

- **Hemorrhage**: Bleeding is often not observed in the early phase of illness, but may manifest later in the course of disease as petechiae, ecchymosis/bruising, oozing from vein puncture sites, or mucosal hemorrhage. During the outbreak in West Africa, approximately 20 percent of patients have unexplained bleeding, which is the most commonly manifested as blood in the stool (about 6 percent).

- **Other findings**: Patients with Ebola virus disease can persist with addition findings such as hiccups, chest pain, shortness of breath, headache, confusion, seizures, and cerebral edema. Liver failure, multi-organ dysfunction, conjunctival infection and dark red discoloration of the soft palate are other common physical findings.

In non-fatal cases, patients typically improve approximately 6 days after the onset of symptoms. The formation of antigen-antibody complexes during recovery may cause acute arthralgias and other symptoms. Fatal disease has been characterized by more severe clinical signs early during infection and progression to multi-organ failure and septic shock. Death typically occurs between days six and sixteen.

**Ebola virus: life cycle and pathogenicity in humans:**

The much-talked about Ebola virus is an encapsulated single-stranded (ss) negative RNA virus belonging to the family Filoviridae.

**Cell and Molecular Biology:**

Electron microscopy studies show that the Ebola virus has a filamentous appearance typically 800 nm long and 80 nm in diameter. Each viral particle or virion consists of a nucleocapsid consisting of the negative ssRNA genome surrounded by the nucleoprotein NP, the polymerase cofactor VP35, the virus specific transcription activator VP30, and the viral RNA polymerase L protein (fig 1). This nucleocapsid is encapsulated by an outer viral envelope originating from the host cell membrane with characteristic 10 nm long viral glycoprotein (GP) spikes. The matrix between the outer viral envelope and the nucleocapsid is occupied by the VP40 and VP24 viral proteins.

In green is the nucleocapsid made of the ssRNA genome and the proteins NP (large green spheres), VP35 (in purple), VP30 (in blue) and L (in grey) proteins. Note that the NP or N, VP35 and L proteins are shown outside the virion for better visibility. The nucleocapsid is surrounded by the outer membrane derived from host cell membrane (in light blue) and is studded with viral GP spikes (yellow studs). The matrix between the nucleocapsid and the outer membrane (in brown) comprises of the VP40 (brown) and VP24 (orange) proteins. Source: Viral Zone (ExPASy).
The virus genome is 19 kb (kilobases) in length, and encodes seven structural and one non-structural protein. The fig below shows the virus genome with the gene order.

**Figure 2:** Diagrammatic representation of the Ebola virus genome.

The leader and the trailer regions are untranscribed sequences which regulate transcription, replication and packaging of genomes into new virions.

The viral RNA polymerase binds at the leader end to initiate sequential transcription of each gene. The newly transcribed mRNAs are capped and polyadenylated by the L protein during this process. Of note, the primary mRNA transcribed from the GP gene encodes a small, non structural, soluble protein called sGP which is secreted from the infected host cells into blood. The fully functional glycoprotein is a result of RNA editing and this protein is expressed on the cell surface as GP spikes. These GP spikes, help in anchorage and membrane fusion of the virion to the host cell, and are a crucial factor for ebola virus pathogenicity.

The matrix protein VP40 is important for maintaining the structural integrity of the virion. It is also associated with endocytosis and virus budding and has the ability to release itself from the cells even in the absence of other viral proteins. The second matrix protein VP24 suppresses interferon production in the host cell. In remaining proteins namely NP, VP35, VP30 and L proteins from the structure components of the nucleocapsid. More, these proteins also catalyse genome transcription and replication.

**6. VIRUS TRANSMISSION**

It is not entirely known how Ebola spreads in humans, but contact with body fluids of infected humans or animals is primarily responsible for the virus outbreak.

Fruit bats are the natural reservoirs of the virus. The US centre for Disease Control has a self-explanatory cartoon depicting the likely method of virus transmission from bats to humans. Fig 3.

**7. THE LIFE-CYCLE OF THE VIRUS**

(1) Host immune system attack

The early targets of the virus are the monocytes and the macrophages of the host immune system and other target cells are liver cells, and endothelial cells. Ebola virus employs different mechanisms to interfere with or even ignore the host immune system completely. Most of these host immune system attack processes involve the virus structural proteins. One such mechanism is called the antibody-dependent enhancement (ADE) wherein the host antibodies (Abs), facilitate or enhance the virus’s attachment to the host cells increasing infection in these cells. The Abs bind to antibody receptors at their Fc sites while the virus binds to the antigen-binding site at the free end of the Abs. In vitro studies in Ebola showed that the virus activates the classical pathway of the complement system. Initially, the Ebola virus binds to its receptor on the host cell surface. Following this, Abs bind to the glycoprotein (GP) spikes of the virus, and the C1q component of the complement enhances the Ab-GP complex to bind to C1q ligands on the host cell surface thus increasing the interaction of the host cell surface. This way, the GP spikes on the virus use the host immune system (Abs and the complement components) to enhance its attachment to the target cells.
The virus is transmitted by contact with contaminated body fluids. Figure 3: Ebola virus transmission from fruit bats to humans.

In addition to ADE, the virus protein VP35, blocks the immune system’s interferon (IFN) pathways comprising of various cytokines that exert anti-viral responses. VP35 blocks IFN response by competing with the protein such as retinoic acid -inducible gene 1 (RIG1) protein to activate the IFN pathway. Along with VP35, VP24 also blocks IFN pathway activation. VP24 blocks transcription factors like STAT1 that regulate transcription of the immune system genes. As aforementioned, the primary mRNA transcript of the GP gene encodes the soluble sGP which is speculated to have an anti-inflammatory role during infection which further enhances the virus’ escape from host immune system response. Moreover, sGP has many similar epitopes with GP, so it could potentially sequester or absorb host Abs to block their downstream action. Thus, the viral proteins disrupt different components of the immune system to attach to the host cell for subsequent entry. In this way, it attacks the immune system of the host cell.

(2) Virus entry into the host cell

The exact mechanism by which the Ebola virus enters host cells remains poorly understood. One general mechanism to infect host cells for most enveloped viruses including the Ebola virus is Endocytosis. Research indicates that the virus utilizes a lipid-dependent, non-clathrin and dynamin-independent endocytic pathway of entry. Macropinocytosis is the most likely mechanism employed by the Ebola virus. This process involves outward extensions of the plasma membrane formed by actin polymerization, which can fold back upon themselves. The distal loop ends of these extensions or membrane ruffles can fuse to form a macropinosome. This also means that actin and its associated polymerising proteins play a pivotal role in virus entry. The exact mechanism by which the virus induces macropinocytosis is not understood. It is speculated that interactions between GP and host cell surface receptors can trigger macropinocytosis to initiate viral entry.

(3) Virus replication

Once inside the host cell, the virus initiates transcription at the leader end of the genome with the binding of the polymerase complex. VP30 is an important transcription activation factor for viral genome transcription, while VP24 is an inhibitor to this process. The exact mechanism of VP24-dependent transcription termination is not fully understood, but it seems to be important for converting the virus from its transcriptional or replication active form to one that is geared for virion assembly and exit from host cell.

(4) Virus budding and exit from host cell

Following replication, the cell loses its connection with other cells as well as attachment to its substrate. Meanwhile, the newly synthesized genomes are packaged into new buds or virions and egresses from the host cell surface with the help of the matrix protein VP40. VP40 interacts with ubiquitin ligase Nedd4 which is a part of human ubiquitination enzyme pathway and links multiple copies of ubiquitin molecules to VP40. VP40 itself is transported to the host cell plasma membrane using the COPII transport system. Once in the plasma membrane, the virus moves through lipid bilayer and is enveloped by the host cell membrane, then buds off and enters the extracellular space.
rafts where the final assembly and budding of the virions occur, before their final exit from the host cell.

Although the structural components of the virus are known, the exact mechanisms by which it causes disease in humans are not completely understood. This poses a major challenge for treatment and to date prevention is the best mode of action to avoid an Ebola outbreak.

8. DIAGNOSIS

It can be difficult to distinguish EVD from other infectious diseases such as malaria, typhoid fever and meningitis because a Confirmation that symptoms are caused by Ebola virus infections are made using the following investigations\textsuperscript{57,61}:

<table>
<thead>
<tr>
<th>Timeline of infection</th>
<th>Diagnostic tests available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Within a few days after symptoms begin</td>
<td>-antigen capture enzyme-linked immunosorbent assay (ELISA) testing</td>
</tr>
<tr>
<td></td>
<td>-igM ELISA</td>
</tr>
<tr>
<td></td>
<td>-polymerase chain reaction (PCR)</td>
</tr>
<tr>
<td></td>
<td>-virus isolation</td>
</tr>
<tr>
<td>Later in disease course or after recovery</td>
<td>-igM and IgG antibodies</td>
</tr>
<tr>
<td>Retrospectively in deceased patients</td>
<td>-immunohistochemistry testing</td>
</tr>
<tr>
<td></td>
<td>-PCR</td>
</tr>
<tr>
<td></td>
<td>-Virus isolation</td>
</tr>
</tbody>
</table>

**Ebola Virus: Development of Vaccines and Therapeutic Drugs**\textsuperscript{62}

The 2014 outbreak of Ebola virus highlights the urgent need to develop an effective vaccine to prevent the spread of this deadly virus, and effective therapies to improve survival rates among those infected with EVD. A DNA vaccine candidate should begin clinical trials in humans this year, and investigational drugs in development to treat patients suffering from viral hemorrhagic fever include monoclonal antibodies, siRNA-based therapeutics, and antiviral small molecule drugs.\textsuperscript{63}

Tekmira’s siRNA-based investigational drug TKM-Ebola has been authorized by FDA under expanded access protocols to be administered to patients diagnosed with or suspected to be infected with Ebola\textsuperscript{64}.

**Recent Research Reports on Ebola**\textsuperscript{61}:

- In April 2014, a group of researchers from the CDC published a study on High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Margab and Ebola viruses, using codon-optimized Ebola virus genes synthesized by Genscript.

- A 2013 Molecular therapy paper report pre-clinical results for a DNA vaccine that protects against Ebola and Marburg in guinea pigs and rodents. Inovia Pharmaceuticals is using its SynCon platform to develop synthetic gene-based vaccine against Ebola, HIV, cancer-causing viruses, and influenza.

- London, Jan 06 (IANS) Oxford University doctors and scientists are starting the first safety trial of an experimental preventative Ebola vaccine, aiming to have vaccinated all 72 healthy adult volunteers by the end of January. Volunteers for the trial, aged from 18-50, will be the first humans to receive the vaccine, which is developed by Jiansee Pharmaceutical Companies of Johnson and Johnson. Xinhux reported citing a press release from the university issued Tuesday. The study involves a prime-boost vaccine regimen, which does not contain any replicating virus, so it in not possible to be infected with Ebola, according to the researchers. Patients are first given a prime immune system to stimulate an initial immune response, and then a boost intended to further enhance the level of the body’s immune response over time.\textsuperscript{64}

**New Ebola Drugs Cures Monkeys in Clinical Trial**\textsuperscript{62}

The cure of the fatal Ebola virus may finally have just been discovered. Recently, there has been reports by scientists of Ebola-infected monkeys being completely cured. The medication, Zmapp, is at present being used to treat patients infected with the virus including William Pooley—a British nurse—who is currently being treated at London-based Royal Free hospital for contacting the disease in Sierra Leone.\textsuperscript{62}

Around 18 monkeys infected with Ebola were found to be totally cured after being administered ZMapp. The results, according to experts, were heavily encouraging. The result revealed that these trials now have a strong backing and should be used in humans. On the other hand, it should be noted that two patients treated with the drugs had died, but it may have been because the drug was administered too late for it to be effective.\textsuperscript{65}

**Ongoing Ebola Drug Development efforts**\textsuperscript{63}:

- Newlink Genetics Crop is poised to begin the first clinical trials of an Ebola vaccine an attenuated live virus, vesicular stomatitis virus (VSV), a common livestock pathogen, into which an Ebola viral coat protein has been introduced.\textsuperscript{66}

- A vaccine currently poised to begin clinical trials as soon as 2014 is a DNA vaccine, containing synthetic genes encoded by the Ebola virus delivered in a non-replicating adenoviral vector. DNA vaccine stimulates a robust immune response to high-level expression of specific antigenic proteins delivered in vector optimized for safety.\textsuperscript{63}

- DNA vaccine efficacy can be enhanced through co-delivery of synthetic genes encoding adjuvants such as cytokinins, chemokines, or synthetic genes encoding.
Researchers at the NIH’s Vaccine Research Center (VRC) have designed a DNA vaccine against Ebola in collaboration with Okairos, which was recently acquired by GSK. This vaccine candidate is composed of a non-replicating chimpanzee adenovirus vector vaccine into which two Ebola genes have been inserted. Clinical trials are expected to begin in fall 2014 with approval coming soon as in 2015.

Several investigational drugs have received FDA permission to be administered to patients infected with Ebola virus, including the monoclonal antibodies cocktail ZMapp and the RNA based therapeutic TKM Ebola.

siRNA delivered through lipid nanoparticles: Tekrimsa is developing the RNAi-based therapeutic TKM. Ebola to combat the Zaire species of ebola virus (ZEBOV).

Prevention and control

Contact tracing, a good laboratory service, safe burials and social mobilization. Raising awareness of risk factor among people against EBOLA virus and their preventive measures if you must travel to an area affected by the 2014 EBOLA outbreak, protect yourself by doing the following:

- Wash hand frequently or use an alcohol-based hand sanitizer.
- Avoid contact with blood and body fluids of any person, particularly someone who is sick.
- Do not touch the one who has died from Ebola.
- Do not touch bats and nonhuman primates or their blood and fluids and do not touch or eat raw meat prepared from these animals.

Other protective measures also are taken by individuals in an effective way to reduce human transmission. Risk reduction messaging should focus on several factors:

- Reducing the risk of wildlife-to-human transmission from contact with infected fruit bats and monkeys/apes and the consumption of their raw meat. Animals should be handled with gloves and other appropriate protective clothing. Animal products (blood and meat) should be thoroughly cooked before consumption.
- Reducing the risk of human-to-human transmission with direct or close contact with people with EVD symptoms, particularly with their body fluids. Gloves and appropriate personal protective equipments should be worn when taking care of ill patients at home.
- Outbreaks containment measures including prompt and safe burial of dead, identifying people who may have been contact with someone infected with Ebola, monitoring the health of contacts for 21 days, the importance of separating the healthy from the sick to prevent further spread, the importance of good hygiene and maintaining a clean environment.
- Information for patients-upto date offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions patient might have about a given condition. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

SUMMARY AND CONCLUSION

Last year 2014 was very drastic for the people who suffered from Ebola virus disease. Our motive to write this review article is only to give the tribute for the patients or persons who died from ebola virus and another is to spread the awareness amongs the peoples for ebola virus by giving their information to the patients and peoples related to their sign and symptoms, diagnose, treatment and precautions for protecting ourself from this disease.

From this article we concluded that the EVD is controlled by either increasing the immune system of the human body by taking Basil leaves and fruits as immunity boosters or by inhibiting the replication of the virus in the host cell by producing Ebola vaccines which is going on research work. More rapidly exiting the virus from the host cell increases the prognosis of the host life is also finding to controlled the EVD.

Currently no vaccine is produced for the EVD but most of the drugs and vaccine are ongoing Ebola Drug Development efforts. If any vaccine or drug will produce, this article will be updated.
REFERENCES


64. Ebola vaccine trail begins in Britain. Available at; https://in.news.yahoo.com/ebola-vaccine-trail-begins-britain-162405851.html